TMPRSS2 and neoplasm: For example, there is some suggestion from their predominantly clonal presence in tumour samples that gain‐of‐function SVs, including certain recurrent oncogenic fusions such as TMPRSS2‐ESG and BRAF‐KIAA1549, occur early in tumour development [95].